Monday, 16 April
Pneumococcal Vaccine Policy for Older Adults: Same Data, Different Recommendations
7:15-8:45
Symposium Organised by MSD
Chair: Robert Booy (Australia)
7:15 The Pneumococcal Vaccine Policy Landscape: Setting the Stage
Robert Booy (Australia)
7:25 Serotype Epidemiology and Evolving Trends
Shelly McNeil (Canada)
7:40 PCV-PPV23 Sequential Policy: the US Experience
Lee Harrison (USA)
8:05 PPV23 only Policy: The Germany Experience
Thomas Weinke (Germany)
8:30 Panel Discussion and Q&A
Tuesday, 17 April
The epidemiology of pneumococcal disease as we approach a decade of higher valent PCV use.
7:15-8:45
Symposium Organised by GSK
Chair: William Hausdorff (Belgium)
07:15 Welcome and Introduction
William Hausdorff (Belgium)
07:20 The evolution of our understanding of PCVs over the past 25 years
William Hausdorff (Belgium)
07:35 Experience on the sequential use of 3 PCVs in New Zealand
Helen Petousis-Harris (New Zealand)
07:55 Public health impact beyond culture-confirmed IPD
Arto Palmu (Finland)
08:15 PCV prevention of Otitis Media and effect on Antibiotic use/resistance
Asgeir Haraldsson (Iceland)
08:35 Panel Discussion and Q&A
Wednesday, 18 April
Determining the Impact of Pneumococcal Vaccination: From Disease Burden to Vaccine Effectiveness
7:15-8:45
Symposium Organised by Pfizer
Chair: Bradford Gessner (USA)
7:15 Welcome and Introductions
Bradford Gessner (USA)
7:20 Public Health Benefits of Prevenar 13 Across the Life Span
Alejandro Cané (Argentina)
7:40 Revisiting the Burden of Community-Acquired Pneumonia in Adults
Julio Ramirez (USA)
8:10 Evaluating Direct Protection in Older Adults: Real-World Effectiveness of PCV13
John McLaughlin (USA)
8:30 Faculty Question and Answer Session
Bradford Gessner (USA)
